AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

From The Motley Fool 2 Nov 2026, 16:00 UTC 1 min read

AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.

Full story

Continue reading this story on The Motley Fool, the publisher that reported it.

Read the full story at The Motley Fool ↗

AI tools

Written by AI from the article text. It can make mistakes; check the original story.

News

Business

National

Discover

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

AI tools

Topics in this story

More from Business

Hyperscalers and Apple surge after election results remove investor uncertainty

How Trump’s Energy Policies Helped Trigger Midterm Rout

Ford's Q3 Sales Slipped. Here's the Silver Lining: Customers Are Splurging on Fancy Trims.

Open source AI is booming. Hugging Face explains who profits.

DuckDuckGo pitches itself to schools amid backlash over Google’s AI policy

Tesla Wants to Build 20,000 Optimus Robots a Week. Here's the Supplier That Gets Paid for Every Single One -- and It's Not Nvidia.